Information Provided By: 
Fly News Breaks for November 18, 2015
RDUS
Nov 18, 2015 | 08:12 EDT
After Radius announced that it would delay filing for FDA approval of its abaloparatide drug by one quarter, Cantor thinks the decline in the stock was "excessive." The firm still believes that the drug's commercial opportunity along with the impact of other drugs from its pipeline, can drive the stock to $85. Cantor keeps an $85 price target and Buy rating on the shares.
News For RDUS From the Last 2 Days
There are no results for your query RDUS
